- Data presented as Developing Topics poster at AAIC 2026 -

LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction up to 75% in key brain regions of non-human primates (NHPs) following a single intravenous (IV) dose over a six-month period.

In June, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year. In May, the Company presented three-month GLP toxicology data for VY1706 at the American Society of Gene & Cell Therapy’s (ASGCT) 2026 Annual Meeting.